Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30206% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Product Revenues — Diagnostic Testing Services by Year
Product Revenues — Diagnostic Testing Services ($M) ($M)
Natera Product Revenues — Diagnostic Testing Services: $2,296M in FY2025, up 36.2% from a year earlier. That is the highest of the 10 years on record here.
Latest, FY2025
2,296
Period ended Dec 31, 2025
Change on a year earlier
+36.2%
1,685 in FY2024
History
10 years
Since FY2016
Sources
6
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (2026-02-27) ↗
Reported in Form 10-K/10-Q (DB).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Product Revenues — Diagnostic Testing Services ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,296 | +36.2% | Form 10-K (2026-02-27) ↗ |
| FY2024 | Dec 31, 2024 | 1,685 | +57.7% | Form 10-K (2025-02-28) ↗ |
| FY2023 | Dec 31, 2023 | 1,069 | +34.0% | Form 10-K (2024-02-29) ↗ |
| FY2022 | Dec 31, 2022 | 797 | +37.4% | Form 10-K (2023-03-01) ↗ |
| FY2021 | Dec 31, 2021 | 580 | +53.5% | Form 10-K (2023-03-01) ↗ |
| FY2020 | Dec 31, 2020 | 378 | +40.0% | Form 10-K (2023-03-01) ↗ |
| FY2019 | Dec 31, 2019 | 270 | +12.3% | Form 10-K (2020-03-02) ↗ |
| FY2018 | Dec 31, 2018 | 240 | +18.0% | Form 10-K (2019-03-15) ↗ |
| FY2017 | Dec 31, 2017 | 204 | -2.7% | Form 10-K (2019-03-15) ↗ |
| FY2016 | Dec 31, 2016 | 209 | – | Form 10-K (2019-03-15) ↗ |
Cite this data
StockData. (2026). Natera Product Revenues — Diagnostic Testing Services ($M), annual FY2016–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/db-seg-product-rev
See every metric in the Natera KPI table. Data updated Nov 2, 2026.